Exubera Bong Bombs!

Pfizer announced that it will no longer market Exubera, an inhaled insulin device that it just began to promote heavily on TV.

Could this have been foreseen? Exubera had long been the butt of many blogger, patient, and even physician joke.

What advice did I give Pfizer that it ignored?

For more on this, read today's post to Pharma Marketing Blog.

For more posts in related topic areas, see:

• DTC Advertising
• Sales & Sales Reps

If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.

The collection of articles and commentary in this first Pharma Marketing News Special Supplement chronicles the emerging issues of direct-to-consumer (DTC) advertising and presents pro and con opinions from experts on how DTC needs to adapt in the post-Vioxx marketing era. Topics include: DTC Pros and Cons, Straight-Talking DTC, Communicating Risk, Biotech DTC, Print DTC, and more.

TABLE OF CONTENTS

Order both Volume One and Volume Two and SAVE! (Click Here)

Order and pay for Volume One now using your credit card

ONLY $29.95
PDF file delivered to you by email (usually within minutes of placing your order):

If you wish to be pay by check or credit card off-line, please use:
Printable Order Form